Blog
RSS FeedPosted by Michael Wonder on 07 Dec 2018
Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs
6 December 2018 - The Canadian patchwork system of prescription drug coverage and the employer sponsored private health benefits group plans ...
Posted by Michael Wonder on 04 Dec 2018
Enstilar is now covered by the Alberta Drug Benefit List for adults with psoriasis vulgaris
3 December 2018 - Leo Pharma Canada has announced that as of 1 December 2018, Enstilar has been added as ...
Posted by Michael Wonder on 03 Dec 2018
Canadian R&D-to-sales ratio for brand-name drug companies less than half of 10% commitment
3 December 2018 - USMCA concessions latest hit to Canadian prescription drug costs. ...
Posted by Michael Wonder on 03 Dec 2018
Canadians with rare lung disease are relieved to now have publicly funded access to potentially life-extending treatment
30 November 2018 - Uptravi now funded for the majority of Canadians with pulmonary arterial hypertension, but other treatments remain ...
Posted by Michael Wonder on 23 Nov 2018
Lessons for Canada from pharmacare systems around the world
23 November 2018 - In its 2018 budget, the federal government created an advisory council on the implementation of national ...
Posted by Michael Wonder on 22 Nov 2018
Canadians giving up necessities, going into debt to pay for prescriptions, study finds
20 November 2018 - Study found 731,000 Canadians across the country borrowed money to pay for medication. ...
Posted by Michael Wonder on 15 Nov 2018
Lowering the price of new drugs comes with too high a cost — Canadians' health
14 November 2018 - Ottawa wants to apply new price regulations, which will only cut manufacturer profits and deter the introduction ...
Posted by Michael Wonder on 13 Nov 2018
Canada's HTA agency releases report on international biosimilar policies
8 November 2018 - The Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian entity responsible for health ...
Posted by Michael Wonder on 31 Oct 2018
Medical cannabis user finds prescription unaffordable now that recreational weed is legal
31 October 2018 - Shane Moore's landlords won't let him grow his own, meaning he'd have to pay $1,500/month for his ...
Posted by Michael Wonder on 29 Oct 2018
Mavenclad (cladribine tablets) receives positive CADTH Canadian Drug Expert Committee recommendation
29 October 2018 - Funding recommendation marks an important step to provide access to this innovative new oral treatment for Canadians ...
Posted by Michael Wonder on 22 Oct 2018
Hatred of big pharma won’t get us better drug prices
22 October 2018 - The story of how Remicade became Canada’s most lucrative drug with sales topping $1.1-billion – told ...
Posted by Michael Wonder on 22 Oct 2018
How pharma companies try to use funding to sway patient advocate groups
21 October 2018 - Like many patient advocacy groups, the Canadian Spondylitis Association – which is focused on arthritis in the ...
Posted by Michael Wonder on 16 Oct 2018
Cystic fibrosis patients worry about future of 'life-changing' drug
16 October 2018 - A drug review body has recommended the drug not be covered by public benefit programs. ...
Posted by Michael Wonder on 11 Oct 2018
Ethics in health technology assessment: a systematic review
9 October 2018 - Integration of ethics into health technology assessment remains challenging for HTA practitioners. ...
Posted by Michael Wonder on 10 Oct 2018
Picking winners & losers among cystic fibrosis patients
10 October 2018 - Twenty-five years ago, Nova Scotia’s then health minister, George Moody, became a national hero. He broke ...